Yang Po-wen explains that due to the limits of the company's size and economic power, it still can't compete with major foreign pharmaceutical companies. But because there's a lower entry bar for producing Chinese medicines such as Agaricus blazei, TaiSugar's biotech division may become its most profitable.
楊博文表示，以台糖目前的規模和實力，尚無法與國外醫藥大廠一拚，但類似「巴西蘑菇」等生醫食品的製造門檻較低，卻仍足以讓生科部成為台糖未來最賺錢的事業體。